- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MRI confirms effectiveness of beta-thalassemia treatment
British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for beta-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for beta-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
Researchers found a 40% increase in T2* values, which represents a statistically significant drop in myocardial iron among beta-thalassemia patients who received a combined deferoxamine/deferiprone treatment for 12 months, according to Dr. Mark A. Tanner, a contrast MR researcher at Royal Brompton Hospital in London. T2* increases in the placebo-treated group were much smaller.
The results suggest that combined deferoxamine/deferiprone therapy will reduce the likelihood of cardiac iron loading and the threat of lethal complications, Tanner said.
"I suggest that combined therapy be considered in all patients who fail to achieve adequate iron load status on deferoxamine alone," he said.
This special section was compiled by James Brice, senior editor of Diagnostic Imaging.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
